Publications by authors named "Elliott R Rodriguez-Lopez"
Article Synopsis
- Cabotegravir (CAB) is a newly approved HIV treatment and prevention method by the FDA and is crucial in combating the HIV epidemic in the USA.
- Its effectiveness can be affected by specific natural polymorphisms in integrase, especially when combined with primary drug-resistance mutations.
- A study found that the T218I and T218S polymorphisms do not significantly impact CAB's effectiveness, integration, or infectivity, indicating they are unlikely to undermine CAB as a treatment option or pre-exposure prophylaxis.
The HIV-1 integrase viral protein is responsible for incorporating the viral DNA into the genomic DNA. The inhibition of viral integration into host cell DNA is part of recent therapeutic procedures. Combination therapy with protease and reverse transcriptase inhibitors has demonstrated good synergistic results in reducing viral replication.
View Article and Find Full Text PDF